Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation.
about
Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101The association of plasma fibrinogen with clinicopathological features and prognosis in esophageal cancer patients.Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study.Prognostic significance of pretreatment plasma fibrinogen in patients with hepatocellular and pancreatic carcinomas: A meta-analysis.Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resectionPrognostic value of plasma fibrinogen in hepatocellular carcinoma: a meta-analysis
P2860
Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic value of combined p ...... a after liver transplantation.
@en
Prognostic value of combined p ...... a after liver transplantation.
@nl
type
label
Prognostic value of combined p ...... a after liver transplantation.
@en
Prognostic value of combined p ...... a after liver transplantation.
@nl
prefLabel
Prognostic value of combined p ...... a after liver transplantation.
@en
Prognostic value of combined p ...... a after liver transplantation.
@nl
P2093
P2860
P356
P1433
P1476
Prognostic value of combined p ...... ma after liver transplantation
@en
P2093
Dong-Ping Wang
Lin-Wei Wu
Qiang Zhao
Qing-Qi Ren
Shun-Jun Fu
Wei-Qiang Ju
Xiao-Feng Zhu
Xiao-Ping Wang
P2860
P304
P356
10.18632/ONCOTARGET.13804
P407
P50
P577
2017-01-01T00:00:00Z